Rapid and Quantitative Assessment of Cancer Treatment Response Using In Vivo Bioluminescence Imaging
Current assessment of orthotopic tumor models in animals utilizes survival as the primary therapeutic end point. In vivo bioluminescence imaging (BLI) is a sensitive imaging modality that is rapid and accessible, and may comprise an ideal tool for evaluating antineoplastic therapies [1 ]. Using hum...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2000-01-01
|
Series: | Neoplasia: An International Journal for Oncology Research |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1476558600800391 |
id |
doaj-08f3af95e6b04c4a88507e079fe74e36 |
---|---|
record_format |
Article |
spelling |
doaj-08f3af95e6b04c4a88507e079fe74e362020-11-25T00:00:24ZengElsevierNeoplasia: An International Journal for Oncology Research1476-55861522-80022000-01-012649149510.1038/sj.neo.7900121Rapid and Quantitative Assessment of Cancer Treatment Response Using In Vivo Bioluminescence ImagingAlnawaz Rehemtulla0Lauren D. Stegman1Shaun J. Cardozo2Sheila Gupta3Daniel E. Hall4Christopher H. Contag5Brian D. Ross6The Center for Molecular Imaging and the Department of Radiation OncologyRadiology, University of Michigan Medical School, 1150 West Medical Center Drive, Medical Sciences Research Building III, Room 9303, Ann Arbor, MI 48109-0648Radiology, University of Michigan Medical School, 1150 West Medical Center Drive, Medical Sciences Research Building III, Room 9303, Ann Arbor, MI 48109-0648Radiology, University of Michigan Medical School, 1150 West Medical Center Drive, Medical Sciences Research Building III, Room 9303, Ann Arbor, MI 48109-0648Radiology, University of Michigan Medical School, 1150 West Medical Center Drive, Medical Sciences Research Building III, Room 9303, Ann Arbor, MI 48109-0648Department of Pediatrics, Stanford University School of Medicine, Stanford, CA 94305-5208Radiology, University of Michigan Medical School, 1150 West Medical Center Drive, Medical Sciences Research Building III, Room 9303, Ann Arbor, MI 48109-0648 Current assessment of orthotopic tumor models in animals utilizes survival as the primary therapeutic end point. In vivo bioluminescence imaging (BLI) is a sensitive imaging modality that is rapid and accessible, and may comprise an ideal tool for evaluating antineoplastic therapies [1 ]. Using human tumor cell lines constitutively expressing luciferase, the kinetics of tumor growth and response to therapy have been assessed in intraperitoneal [2], subcutaneous, and intravascular [3] cancer models. However, use of this approach for evaluating orthotopic tumor models has not been demonstrated. In this report, the ability of BLI to noninvasively quantitate the growth and therapeuticinduced cell kill of orthotopic rat brain tumors derived from 9L gliosarcoma cells genetically engineered to stably express firefly luciferase (9LLuc) was investigated. Intracerebral tumor burden was monitored over time by quantitation of photon emission and tumor volume using a cryogenically cooled CCD camera and magnetic resonance imaging (MRI), respectively. There was excellent correlation (r=0.91) between detected photons and tumor volume. A quantitative comparison of tumor cell kill determined from serial MRI volume measurements and BLI photon counts following 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) treatment revealed that both imaging modalities yielded statistically similar cell kill values (P=.951). These results provide direct validation of BLI imaging as a powerful and quantitative tool for the assessment of antineoplastic therapies in living animals. http://www.sciencedirect.com/science/article/pii/S1476558600800391luciferasebioluminescencein vivo imagingcell killtherapeutic response |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Alnawaz Rehemtulla Lauren D. Stegman Shaun J. Cardozo Sheila Gupta Daniel E. Hall Christopher H. Contag Brian D. Ross |
spellingShingle |
Alnawaz Rehemtulla Lauren D. Stegman Shaun J. Cardozo Sheila Gupta Daniel E. Hall Christopher H. Contag Brian D. Ross Rapid and Quantitative Assessment of Cancer Treatment Response Using In Vivo Bioluminescence Imaging Neoplasia: An International Journal for Oncology Research luciferase bioluminescence in vivo imaging cell kill therapeutic response |
author_facet |
Alnawaz Rehemtulla Lauren D. Stegman Shaun J. Cardozo Sheila Gupta Daniel E. Hall Christopher H. Contag Brian D. Ross |
author_sort |
Alnawaz Rehemtulla |
title |
Rapid and Quantitative Assessment of Cancer Treatment Response Using In Vivo Bioluminescence Imaging |
title_short |
Rapid and Quantitative Assessment of Cancer Treatment Response Using In Vivo Bioluminescence Imaging |
title_full |
Rapid and Quantitative Assessment of Cancer Treatment Response Using In Vivo Bioluminescence Imaging |
title_fullStr |
Rapid and Quantitative Assessment of Cancer Treatment Response Using In Vivo Bioluminescence Imaging |
title_full_unstemmed |
Rapid and Quantitative Assessment of Cancer Treatment Response Using In Vivo Bioluminescence Imaging |
title_sort |
rapid and quantitative assessment of cancer treatment response using in vivo bioluminescence imaging |
publisher |
Elsevier |
series |
Neoplasia: An International Journal for Oncology Research |
issn |
1476-5586 1522-8002 |
publishDate |
2000-01-01 |
description |
Current assessment of orthotopic tumor models in animals utilizes survival as the primary therapeutic end point. In vivo bioluminescence imaging (BLI) is a sensitive imaging modality that is rapid and accessible, and may comprise an ideal tool for evaluating antineoplastic therapies [1 ]. Using human tumor cell lines constitutively expressing luciferase, the kinetics of tumor growth and response to therapy have been assessed in intraperitoneal [2], subcutaneous, and intravascular [3] cancer models. However, use of this approach for evaluating orthotopic tumor models has not been demonstrated. In this report, the ability of BLI to noninvasively quantitate the growth and therapeuticinduced cell kill of orthotopic rat brain tumors derived from 9L gliosarcoma cells genetically engineered to stably express firefly luciferase (9LLuc) was investigated. Intracerebral tumor burden was monitored over time by quantitation of photon emission and tumor volume using a cryogenically cooled CCD camera and magnetic resonance imaging (MRI), respectively. There was excellent correlation (r=0.91) between detected photons and tumor volume. A quantitative comparison of tumor cell kill determined from serial MRI volume measurements and BLI photon counts following 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) treatment revealed that both imaging modalities yielded statistically similar cell kill values (P=.951). These results provide direct validation of BLI imaging as a powerful and quantitative tool for the assessment of antineoplastic therapies in living animals.
|
topic |
luciferase bioluminescence in vivo imaging cell kill therapeutic response |
url |
http://www.sciencedirect.com/science/article/pii/S1476558600800391 |
work_keys_str_mv |
AT alnawazrehemtulla rapidandquantitativeassessmentofcancertreatmentresponseusinginvivobioluminescenceimaging AT laurendstegman rapidandquantitativeassessmentofcancertreatmentresponseusinginvivobioluminescenceimaging AT shaunjcardozo rapidandquantitativeassessmentofcancertreatmentresponseusinginvivobioluminescenceimaging AT sheilagupta rapidandquantitativeassessmentofcancertreatmentresponseusinginvivobioluminescenceimaging AT danielehall rapidandquantitativeassessmentofcancertreatmentresponseusinginvivobioluminescenceimaging AT christopherhcontag rapidandquantitativeassessmentofcancertreatmentresponseusinginvivobioluminescenceimaging AT briandross rapidandquantitativeassessmentofcancertreatmentresponseusinginvivobioluminescenceimaging |
_version_ |
1725445229024116736 |